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Hypotension induced by interleukin-3 in
patients on angiotensin-converting enzyme
inhibitors
SiR-The use of haematopoietic growth factors is increasing.
It is, therefore, essential to demonstrate their efficacy and
safety when given with other commonly prescribed
medicines. We treated 26 patients with ovarian or small-cell
undifferentiated cancers with chemotherapy followed by
recombinant human interleukin-3 (rhIL-3) (0-125-7-5 J-Lg/kg
daily).’ 3 of these patients were also receiving angiotensin-
converting enzyme (ACE) inhibitors for hypertension. All 3
developed marked hypotension (WHO toxicity grade 2 or 3)
within 1-4 hours of the first rhIL-3 injection. In all 3
patients discontinuation of the ACE inhibitor while
continuing rhIL-3 resulted in return of the blood pressure to
normal. After stopping rhIL-3 the blood pressure increased
and ACE inhibitors were again required. Hypotension was
not observed in 22 patients given rhIL-3 without ACE
inhibitors. 1 other patient, not receiving an ACE inhibitor,
became hypotensive during a period of neutropenic fever.
The fever resolved with antibiotic therapy.
The hypotensive effects of ACE inhibitors are mediated by
inhibiting the conversion of angiotensin I into angiotensin II
(a powerful vasoconstrictor). Additionally, inhibition of
kinase II reduces the breakdown of bradykinin, resulting in
vasodilation.2 Furthermore, rhIL-3 stimulates the synthesis
of secondary cytokines (eg, IL-6) and histamine.4 The
hypotension induced by these substances is mediated via
nitric oxide (NO). Both bradykinin and histamine stimulate
rapid (within minutes) NO production by activation of
constitutive NO synthase. Cytokines, including IL-6, cause a
late and more sustained NO generation via an inducible NO
synthase found in endothelium and vascular smooth
muscle.5
The urine from 1 of the hypotensive patients was assayed
for nitrate and cGMP, as indicators of in-vivo NO
production. In the first chemotherapy cycle without rhIL-3
the 24-hour urinary nitrate and cGMP excretion did not
exceed 1 mmol and 1 pmol, respectively. In the second cycle
with rhIL-3, 24-hour nitrate excretion rose from 0-9 mmol
before chemotherapy and 0-8 mmol before rhIL-3 to 5-7
mmol on day 5 of rhIL-3 administration. cGMP rose from
0-9 jjbmol to 2-6 )JLmol on day 5. In another 16 patients, not
receiving ACE inhibitors and not developing hypotension,
24-hour nitrate was measured in 9 and 26 cycles of
chemotherapy with and without rhIL-3, respectively. In
none of these cycles did the 24-hour nitrate excretion exceed
1-3 mmol (control cycles 0-7 [SE 0-3] mmol; cycles with
rhIL-3 0-8 [0-3] mmol).
These data suggest that NO generated in vessel walls by
bradykinin and histamine (via constitutive NO synthase) and
secondary cytokines (via inducible NO synthase) were
responsible for the increase of urinary nitrate and cGMP.
Without priming by ACE inhibitors, the effects of rhIL-3
were too small to lower blood pressure or could easily be
compensated by counter-regulatory mechanisms. We
suggest that synergism between forces acting to generate
NO, in the absence of the counteracting effects of
angiotensin II, were responsible for the rapid induction of
hypotension in patients treated with ACE inhibitors
combined with rhIL-3.
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Nitric oxide in ulcerative colitis
SiR-Lundberg and colleagues (Dec 17, p 1673) suggest
that nitric oxide (NO) concentrations in the colonic lumen
might be increased in ulcerative colitis. The
chemiluminescence method used by these workers depends
on the release of energy from the reaction of NO with ozone,
and is therefore not truly direct. Ozone is a reactive species
and the colonic lumen contains many gaseous substances, so
there is doubt as to its specificity under these conditions.
H2S in particular may react with ozone to produce
chemiluminescent species, and is known to be raised in
ulcerative colitis.
We have evidence that the concentration of NO might be
increased in ulcerative colitis, with a molecule-specific
technique. The rectal lumen in 8 patients with active disease
and 8 controls was perfused for 1 h with a nitrogen stream,
and NO was collected in a cold trap at -196&deg;C. The NO
thus obtained was measured by infrared diode laser
spectroscopy. This technique allows high detection
sensitivity and specificity and we have checked that the
following gases have no absorptions overlapping the NO
transitions used in the measurements: H2O, H2S, CH4, CO,
CO2, N2O, NO2, N2033 NO4. The estimated minimum
detectable amount of NO was 0-1 nmoL. NO was detected
in 4 of 8 patients with active ulcerative colitis but in none of
the controls (p<005). The amounts measured varied from
0-13 to 1.nmoL. Patients negative for NO all had blood
visible in the rectum and the collection tubing.
NO is avidly bound by haemoglobin and we suspect that
this was why we could not detect it in 4 of our patients. If
the technique used by Lundberg and co-workers were truly
specific for NO, we would have expected them to encounter
the same difficulty. Nevertheless, Lundberg and colleagues’
work supports our observation that NO synthesis is
increased in ulcerative colitis,’ a finding that could prove to
be of both pathogenetic and therapeutic importance.
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SIR-Lundberg and colleagues’ study complements our own
investigation showing raised serum concentrations of NO
metabolites in 26 patients with severe attacks of ulcerative
colitis.’ However, in that study concentrations of C-reactive
protein were shown to predict clinical outcome more
accurately than NO metabolites. Lundberg’s data concern
us on several counts.
Only 6 patients were investigated, on one occasion only.
Lundberg and co-workers did not correlate NO
concentrations with disease activity or response to medical
therapy. Without this information, their attempts to draw
conclusions about the effects of corticosteroids on NO
